Literature DB >> 30636915

Utility and Limitation of Preoperative Neutrophil Lymphocyte Ratio as a Prognostic Factor in Hepatocellular Carcinoma.

Ei Uchinaka1, Masataka Amisaki1, Masaki Morimoto1, Naruo Tokuyasu1, Teruhisa Sakamoto1, Soichiro Honjo1, Hiroaki Saito1, Yoshiyuki Fujiwara1.   

Abstract

BACKGROUND: The neutrophil lymphocyte ratio (NLR) has been proposed to be a surrogate marker of inflammation and immunological status and to have prognostic value in various malignancies. This study was conducted to clarify the prognostic significance of preoperative NLR in hepatocellular carcinoma (HCC).
METHODS: We enrolled 135 patients with histologically-proven HCC who underwent initial curative hepatectomy. Based on the median NLR values, patients were divided into: NLR ≥ 2.0 (NLR-high, n = 69) and NLR < 2.0 (NLR-low, n = 66).
RESULTS: In univariate analysis, the 5-year overall survival (OS) rates were 59.8 % ± 6.7% and 75.6% ± 6.5% (P = 0.028) in the NLR-high and NLR-low groups, respectively. Furthermore, the 5-year disease specific survival rates were 68.6% ± 6.7%, and 81.2 ± 6.4% (P = 0.048) in the NLR-high and NLR-low groups, respectively.
CONCLUSION: Our results showed that high NLR was an independent predictor for OS in hepatectomy-treated HCC, suggesting that NLR may be a novel prognostic biomarker for HCC. On the other hand, NLR also has a limitation to predict postoperative prognosis of HCC patients by itself.

Entities:  

Keywords:  hepatocellular carcinoma; liver resection; neutrophil-lymphocyte ratio; prognostic factor

Year:  2018        PMID: 30636915      PMCID: PMC6308101     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  36 in total

1.  Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort.

Authors:  R T Poon; I O Ng; S T Fan; E C Lai; C M Lo; C L Liu; J Wong
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

2.  Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill.

Authors:  R Zahorec
Journal:  Bratisl Lek Listy       Date:  2001       Impact factor: 1.278

3.  Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis.

Authors:  P Shamamian; J D Schwartz; B J Pocock; S Monea; D Whiting; S G Marcus; P Mignatti
Journal:  J Cell Physiol       Date:  2001-11       Impact factor: 6.384

Review 4.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

5.  Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

Authors:  D Gomez; S Farid; H Z Malik; A L Young; G J Toogood; J P A Lodge; K R Prasad
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

6.  Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.

Authors:  Iwao Ikai; Shigeki Arii; Masamichi Kojiro; Takafumi Ichida; Masatoshi Makuuchi; Yutaka Matsuyama; Yasuni Nakanuma; Kiwamu Okita; Masao Omata; Kenichi Takayasu; Yoshio Yamaoka
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

Review 7.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

8.  Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy.

Authors:  S Arii; J Tanaka; Y Yamazoe; S Minematsu; T Morino; K Fujita; S Maetani; T Tobe
Journal:  Cancer       Date:  1992-02-15       Impact factor: 6.860

9.  Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor.

Authors:  Yoka H Kusumanto; Wendy A Dam; Geke A P Hospers; Coby Meijer; Nanno H Mulder
Journal:  Angiogenesis       Date:  2003       Impact factor: 9.596

10.  Serum C-reactive protein levels predict survival in hepatocellular carcinoma.

Authors:  Sakae Nagaoka; Takafumi Yoshida; Junji Akiyoshi; Jun Akiba; Takuji Torimura; Hisashi Adachi; Junichi Kurogi; Nobuyoshi Tajiri; Kinya Inoue; Takashi Niizeki; Hironori Koga; Tsutomu Imaizumi; Masamichi Kojiro; Michio Sata
Journal:  Liver Int       Date:  2007-10       Impact factor: 5.828

View more
  5 in total

1.  Prognostic Significance of Pre-surgical Combined Platelet Count and Neutrophil-Lymphocyte Ratio for Patients With Hepatocellular Carcinoma.

Authors:  E I Uchinaka; Masataka Amisaki; Takuki Yagyu; Masaki Morimoto; Joji Watanabe; Naruo Tokuyasu; Teruhisa Sakamoto; Soichiro Honjo; Hiroaki Saito; Yoshiyuki Fujiwara
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

2.  Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes.

Authors:  Abu Bakar Hafeez Bhatti; Ammal Imran Qureshi; Rizmi Tahir; Talal Almas; Atif Rana
Journal:  Ann Med Surg (Lond)       Date:  2021-07-10

3.  Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.

Authors:  Wei Xu; Ruineng Li; Fei Liu
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

4.  Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy.

Authors:  Yi-Xing Chen; Zhao-Chong Zeng; Yuan Zhuang; Bao-Ying Yuan; Yong Hu; Gen-Wen Chen; Li Zhang; Xiao-Mei Zhao
Journal:  Cancer Manag Res       Date:  2019-12-31       Impact factor: 3.989

5.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.